Wilson Therapeutics AB (publ) Interim Report January 1 – June 30, 2017

Preparations for Phase 3 progressing

April 1 – June 30, 2017

• Net sales amounted to SEK 0.0 M (0.0)
• Loss for the period was SEK 54.6 M (loss: 26.9)
• Loss per share, before and after dilution, totaled SEK 2.12 (loss:1.66)
• At June 30, cash and cash equivalents amounted to SEK 308.3 M (435.6)

January 1 – June 30, 2017

• Net sales amounted to SEK 0.0 M (0.0)
• Loss for the period was SEK 86.0 M (loss: 49.2)
• Loss per share, before and after dilution, totaled SEK 3.34 (loss: 5.86)

Significant events during the period January 1 – June 30, 2017

• Extraordinary general meeting was held in January 2017 and resolved to implement the long term incentive program LTIP 2016
• Data from the successfully completed Phase 2 trial were presented at major scientific conferences
• Board strengthened by the appointments of Dr. Birgitte Volck and Dr. Björn Odlander
• The AGM resolved to implement the long term incentive program LTIP 2017 
• US Orphan Drug Designation granted for WTX101 for the treatment of ALS

”During the first half of the year, we presented final data from our successful Phase 2 trial at various international medical conferences. In parallel, we have focused on the preparations for the pivotal Phase 3 trial, and approximately 30 clinical sites in the EU, the US and Israel have now been selected for participation in the study. The proposed Phase 3 study protocol, using copper control as primary endpoint, has been submitted to the FDA. We are currently awaiting their feedback and, provided no significant issues arise in the review process, we aim to initiate the trial before the end of 2017.”

Jonas Hansson, CEO of Wilson Therapeutics.

Invitation to telephone conference
All interested parties are invited to participate in a web-cast telephone conference regarding the report today August 24 at 10:00 CET. The live webcast and a recorded on-demand version including the presentation material will be accessible at: https://tv.streamfabriken.com/wilson-therapeutics-q2-2017. Questions can be asked in writing via the webcast or verbally via the conference call.

To participate in the conference call, please call one of the following numbers:

• SE: +46 8 566 426 90
• UK: +44 203 008 9804
• US: +1 855 753 2235

The presentation material will also be published before the conference starts on Wilson Therapeutics’ website www.wilsontherapeutics.com under Media & Investors/ Presentations. The webcast, and later the recorded version of the webcast and the conference call, will also be accessible via Wilson Therapeutics’ website.

About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, WTX101, is in development as a novel treatment for Wilson Disease. A Phase 2 clinical study has been successfully completed and preparations for a pivotal Phase 3 study are ongoing. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.

Visit www.wilsontherapeutics.com for more information.

For further information contact:
Jonas Hansson, CEO, Wilson Therapeutics AB
Telephone: +46 8 796 00 00
Email: jonas.hansson@wtx.se

Wilson Therapeutics AB (publ)
Corp. Reg. No. 556893-0357
Kungsgatan 3
SE-111 43 Stockholm

The information in the interim report is information that Wilson Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on August 24, 2017.

Tags: